Combination therapy of human pancreatic cancer implanted in nude mice by oral fluoropyrimidine anticancer agent (S-1) with interferon-alpha

Cancer Chemotherapy and Pharmacology

Volumn 59, Issue 1, 2007, Pages 113-126

  Miyake, Kotaro ^a   Tsuchida, Kunihiro ^b   Sugino, Hiromu ^a   Imura, Satoru ^a   Morine, Yuji ^a   Fujii, Masahiko ^a   Shimada, Mitsuo ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b FUJITA HEALTH UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Antitumor effect; DNA microarray; Interferon alpha; Pancreatic cancer; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ALPHA INTERFERON; ANGIOGENIC FACTOR; ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; CD31 ANTIGEN; CYCLINE; FLUOROPYRIMIDINE DERIVATIVE; GELATINASE A; GELATINASE B; MATRILYSIN; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER INVASION; CANCER TRANSPLANTATION; CONTROLLED STUDY; DNA MICROARRAY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFICACY; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; METASTASIS; MICROVASCULATURE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PANCREAS CANCER; PRIORITY JOURNAL; STAINING; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, CD31; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIHYDROURACIL DEHYDROGENASE (NADP); DNA, COMPLEMENTARY; FIBROBLAST GROWTH FACTOR 2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; INTERFERON-ALPHA; MATRIX METALLOPROTEINASES; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PANCREATIC NEOPLASMS; PROLIFERATING CELL NUCLEAR ANTIGEN; SURVIVAL ANALYSIS; TEGAFUR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33751300312     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0250-5     Document Type: Article

References (40)

1. Parker SL, Tong T, Bolden S, Wingo PA (1997) Cancer statistics. CA Cancer J Clin 47:5-27
2. Yeo CJ, Cameron JL (1999) Pancreatic cancer. Curr Probl Surg 36:59-152
3. Isaacs A, Lindenmann J (1957) Virus interference I. The interferon. Proc R Soc Lond 147:258-267
4. Baron S, Dianzani F (1994) The interferons: a biological system with therapeutic potential in viral infections. Antiviral Res 24:97-110
5. Hertzog PJ, Hwang SY, Kola I (1994) Role of interferons in the regulation of cell proliferation, differentiation and development. Mol Reprod Dev 39:226-232
6. Gutterman JU (1994) Cytokine therapeutics: lessons from interferon-α. Proc Natl Acad Sci USA 91:1198-1205
7. Krown SE (1988) Interferons in malignancy: biological products or biological response modifiers? J Natl Cancer Inst (Bethesda) 80:306-309
8. Singh RK, Bucana CD, Gutman M, Fan D, Wilson MR, Fidler IJ (1994) Organ-site dependent expression of bFGF in human renal cell carcinoma cells. Am J Pathol 145:365-374
9. Oliveira IC, Sciavolino PJ, Lee TH, Vilcek J (1992) Downregulation of interleukin-8 gene expression in human fibroblasts: unique mechanism of transcriptional inhibition of interferon. Proc Natl Acad Sci USA 89:9049-9053
10. Fabra A, Nakajima M, Bucana CD, Fidler IJ (1992) Modulation of the invasive phenotype of human colon carcinoma cells by fibroblasts from orthotopic or ectopic organs of nude mice. Differentiation 52:101-110
11. Schiller JH, Storer B, Bittner G, Willson JK, Borden EC (1988) Phase II trial of a combination of interferon-β ser and interferon-γ in patients with advanced malignant melanoma. J Interferon Res 8:581-589
12. Shirasaka T, Nakano K, Fukushima M, Takechi T, Satake H, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Takeda S, Unemi N, Fukushima M (1996) Antitumor activity of 1 M-tegaful- 0.4 M 5-chloro-2, 4-dihydroxypyridine-1M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 56:2602-2606
13. Au JL, Sadee W (1980) Activation of Ftorafur [R,S-1-(tetrahydro-2- furanyl)-5-fluorouracil] to 5-fluorouracil and gamma-butyrolactone. Cancer Res 40:2814-2819
14. Tatsumi K, Fukushima M, Shirasaka T, Fujii S (1987) Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 78:748-755
15. Shirasaka T, Shimamoto Y, Fukushima M (1993) Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 53:4004-4009
16. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T (1998) Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34:1715-1720
17. Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K, Taguchi T (2000) Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. Br J Cancer 83:141-145
18. Hayashi K, Imaizumi T, Uchida K, Kuromachi H, Takasaki K (2002) High response rates in patients with pancreatic cancer using the novel oral fluoropyrimidine S-1. Oncol Rep 9:1355-1361
19. Wadler S, Schwartz EL, Goldman M, Lyver A, Itri L, Wiernik PH (1988) Preclinical and clinical studies of 5-fluorouracil (FURA) and recombinant α-2a-interferon (IFN) against gastrointestinal (GI) malignancies. Clin Res 36:803A
20. Sakon M, Nagano H, Dono K, et al (2002) Combined intraarterial 5-fluorouracil and subcutaneous interferon-α therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 94:435-442
21. Schwartz EL, Hoffman M, O'Connor CJ, Wadler S (1992) Stimulation of 5-fluorouracil metabolic activation by interferon-α in human colon carcinoma cells. Biochem Biophys Res Commun 182:1232-1239
22. Elias L, Sandoval JM (1989) Interferon effects upon fluorouracil metabolism by HL-60 cells. Biochem Biophys Res Commun 163:867-874
23. Eguchi H, Nagano H, Yamamoto H et al (2000) Augmentation of antitumor activity of 5-fluorouracil by interferon-α is associated with up-regulation of p27Kip1 in human hepatocellular carcinoma cells. Clin Cancer Res 6:2881-2890
24. Bruns CJ, Harbison MT, Kuniyasu H, Eue I, Fidler IJ (1999) In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia 1:50-62
25. Tominaga H, Ishiyama M, Ohseto F (1999) A water-soluble tetrazolium salt useful for colorimetric cell viability assay. Anal Commun 36:47
26. Wen Y, Yan DH, Wang B, Spohn B, Ding Y, Shao R, Zou Y, Xie K, Hung MC (2001) p202, an interferon-inducible protein, mediates multiple antitumor activities in human pancreatic cancer xenograft models. Cancer Res 61:7142-7147
27. Vecchi A, Garlanda C, Lampugnani MG, Resnati M, Matteucci C, Stoppacciaro A, Schnurch H, Risau W, Ruco L, Mantovani A (1994) Monoclonal antibodies specific for endothelial cells of mouse blood vessels: their application in the identification of adult and embryonic endothelium. Eur J Cell Biol 63:247-254
28. Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med 324:1-8
29. Spears CP, Shahinian AH, Moran RG, Heidelberger C, Corbett TH (1982) In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. Cancer Res 42:450-456
30. Terashima M, Irinoda T, Fujiwara H (2002) Roles of thymidylate synthase and dihydropyrimidine dehydrogenase on tumour progression and sensitivity to 5-fluorouracil in human gastric cancer. Anticancer Res 22:761-768
31. Takechi K, Tamura H, Yamaoka K, Sakurai H (1997) Pharmacokinetic analysis of free radicals by in vivo BCM (blood circulation monitoring)-ESR method. Free Radic Res 26:483-496
32. Kaneko S, Urabe T, Kobayashi K (2002) Combination chemotherapy for advanced hepatocellular carcinoma complicated by major portal vein thrombosis. Oncology 62:69-73
33. Picozzi VJ, Kozarek RA, Traverso LW (2003) Interferon-based adjuvant chemoradiation therapy after pancreatico-duodenectomy for pancreatic adenocarcinoma. Am J Surg 185:4767-4780
34. Schwartz EL, Hoffman M, O'Connor CJ, Wadler S (1992) Stimulation of 5-fluorouracil metabolic activation by interferon-α in human colon carcinoma cells. Biochem Biophys Res Commun 182:1232-1239
35. Elias L, Sandoval JM (1989) Interferon effects upon fluorouracil metabolism by HL-60 cells. Biochem Biophys Res Commun 163:867-874
36. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7:548-557
37. Fukushima M, Satake H, Uchida J, Shimamoto Y, Kato T, Okabe H (1998) Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts. Int J Oncol 13:693-698
38. Fidler IJ, Ellis LM (1994) The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79:185-188
39. Wagener DJ, Wils JA, Kok TC, Planting A, Couvreur ML, Baron B (2002) Results of a randomised phase II study of cisplatin plus 5-fluorouracil versus cisplatin plus 5-fluorouracil with alpha-interferon in metastatic pancreatic cancer: an EORTC gastrointestinal tract cancer group trial. Eur J Cancer 38:648-653
40. Furudoi A, Tanaka S, Haruma K, Kitadai Y, Yoshihara M, Chayama K, Shimamoto F (2002) Clinical significance of vascular endothelial growth factor C expression and angiogenesis at the deepest invasive site of advanced colorectal carcinoma. Oncology 62:157-166